| Heading: |
Abiraterone |
| Question ID: |
1795158 |
| UIN: |
46587 |
| House: |
Commons |
| Date tabled: |
2025-04-17 |
| Asking Member ID: |
5326 |
| Asking Member display name: |
Edward Morello
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Edward Morello
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Excellence has had discussions with its counterparts in (a) Scotland, (b) Wales, and (c) Northern Ireland on recommending abiraterone acetate for |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-29 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Decisions on the availability of medicines in Scotland, Wales, and Northern Ireland are a matter for the devolved administrations. |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |